Immunotherapy drug cemiplimab takes on aggressive breast cancer in new trial
NCT ID NCT04243616
First seen Jun 26, 2026 · Last updated Jul 28, 2026 · Updated 2 times
Summary
This phase 2 trial is testing whether adding the immunotherapy drug cemiplimab (Libtayo) to standard chemotherapy can eliminate more cancer before surgery in people with high-risk or locally advanced breast cancer. The study enrolls 36 participants with either hormone receptor-positive or triple-negative breast cancer that expresses PD-L1. The main goal is to see how many achieve a pathological complete response—meaning no cancer remains in the breast or lymph nodes after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cemiplimab (Libtayo) plus chemotherapy (paclitaxel, carboplatin, doxorubicin, cyclophosphamide)
- What this could lead to
- If successful, this could point toward a more effective pre-surgery treatment for aggressive breast cancers, potentially improving long-term outcomes.
- What could go wrong
- This is a small, early-phase trial with only 36 participants, so results may not apply broadly. The added immunotherapy can cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Froedtert Hospital & Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can sound waves replace the scalpel for breast tumors?
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Virtual therapy may ease breast cancer treatment side effects
- A gentle jog might be the key to better sleep for breast cancer survivors
- Can mapping tumor DNA unlock personalized breast cancer care?